Mucosal immunity-stimulating agent, and oral pharmaceutical composition for treating hpv infection

A technology of mucosal immunity and stimulant, which is applied in the directions of drug combination, drug delivery, microorganisms, etc., can solve the problems of not providing HPV vaccine for cervical cancer patients and not developing it.

Inactive Publication Date: 2015-02-25
THE UNIV OF TOKYO
View PDF12 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0041] However, as a therapeutic HPV vaccine that has sufficient clinical effects not only for the above-mentioned precancerous lesion patients but also for cervical cancer patients, it is the status quo that a satisfactory vaccine has not yet been found.
[0042] That is, there is still the problem that there is no HPV vaccine for treatment that has a sufficient clinical effect on cervical cancer patients.
[0043] In addition, there is also the problem of not developing a method for effectively inducing acquired immunity against the above-mentioned HPV by oral administration of the above-mentioned LacE7 or HPV vaccines other than the above-mentioned LacE7 in a smaller amount and for a short period of time. It is an HPV-specific cellular immunity induction method in the mucosa
[0064] However, no satisfactory mucosal immunostimulator has been found as a mucosal immunostimulant administered in combination with a vaccine against the above-mentioned virus and bacteria in the prevention of infection by viruses such as HPV or the treatment of infectious diseases.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mucosal immunity-stimulating agent, and oral pharmaceutical composition for treating hpv infection
  • Mucosal immunity-stimulating agent, and oral pharmaceutical composition for treating hpv infection
  • Mucosal immunity-stimulating agent, and oral pharmaceutical composition for treating hpv infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0224]

[0225] Oral immunization with the LacE7 preparation of mice was carried out according to the method described in K. Adachi et al., Vaccine, 2010, vol.28, pp.2810-2817. At this time, Shiquan Dabu Decoction (hereinafter referred to as "JTT") and Buzhong Yiqi Decoction (hereinafter referred to as "HET") were orally administered to the mice as needed, and further Drug LTB polypeptide or synthetic ceramide (αGalCer).

[0226] >

[0227] LacE7 preparations were produced according to known methods (PooH. et al., Int. J. Immunol., 2006, vol. 119, pp. 1702-1709). Briefly, in Lactobacillus casei for which the inducibility of helper T cell type 1 (Th1 cells) was confirmed, the mutant E7 protein (composed of the amino acid sequence shown in SEQ ID NO: 3 amino acid residues in the Rb binding site of the protein were substituted). The cultured recombinant (LacE7) was killed by heat. LacE7 purified from the culture medium was washed several times with distilled water, dried an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A mucosal immunity-stimulating agent comprises a Kampo medicine having a revitalizing activity and a mucosal adjuvant. An oral pharmaceutical composition for treating HPV infection comprises at least E7 polypeptide of HPV and a Kampo medicine having a revitalizing activity.

Description

technical field [0001] The present invention relates to a mucosal immune stimulant and an oral pharmaceutical composition for treating HPV infection. An oral pharmaceutical composition for the treatment of HPV infection of a traditional Chinese medicine having a nourishing and strengthening effect. Background technique [0002] Human papillomavirus (HPV) is a DNA virus, and more than 100 different types have been reported so far. Skin (eg HPV-1, HPV-2) or mucosal surface (eg HPV-6, HPV-11) is infected with the above HPV, thereby forming benign tumors (warts) that exist in units of several months to years. [0003] Furthermore, mucous membranes are infected with some of the above-mentioned HPVs (for example, HPV-16, HPV-18, HPV-31, HPV-33) for a long period of time, thereby causing malignant tumors. [0004] As a female-specific cancer, about 100% of cervical cancer, which has a high prevalence rate next to breast cancer, is caused by the long-term infection of the genitals...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K35/747A61K36/25A61K38/00A61K39/12A61K39/39A61P35/00A61P37/04C07K14/01C12N1/20C12N1/21C12N15/09A61K39/00
CPCA61K9/006C07K14/34A61K2039/541C07K14/28C12N2710/20034A61K2039/55594A61K38/00C07K14/235C07K14/245C07K14/025A61K45/06A61K2039/55511A61K2039/542C12N2710/20022A61K39/12A61K39/39A61P15/00A61P31/20A61P35/00A61P37/04A61P31/22A61K36/25A61K38/16A61K35/74A61K35/747C07K14/335C12N7/00
Inventor 川名敬田口步
Owner THE UNIV OF TOKYO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap